公开(公告)号：US20220064186A1

公开(公告)日：2022-03-03

申请号：US17415237

申请日：2019-12-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Roxana F. Schlam ,  Nicolas Cuniere ,  Victoria A. Mbachu ,  Zhongping Shi ,  Petinka I. Vlahova

IPC: C07D513/04 ,  C07C55/10 ,  C07C59/265 ,  A61K45/06 ,  A61K31/433 ,  A61P7/02

Abstract: The present invention relates to co-crystals of the compound of formula (I), wherein the co-former molecule is succinic acid or citric acid, processes for the preparation of the co-crystal, pharmaceutical compositions thereof, and methods of using the co-crystals for treating or preventing thromboembolic disorders.

公开(公告)号：US09518058B2

公开(公告)日：2016-12-13

申请号：US14914330

申请日：2014-08-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Martin D. Eastgate ,  Gregory L. Beutner ,  Benjamin Cohen ,  Nicolas Cuniere ,  Lopa V. Desai ,  Monica Fitzgerald ,  Qi Gao ,  Michael Bryan Hay ,  Michael Joseph Lawler ,  Paul C. Lobben ,  Christopher S. Regens ,  Thorsten Rosner ,  Neil Strotman ,  Carolyn S. Wei ,  Yi Xiao ,  Bin Zheng ,  Keming Zhu

IPC: C07D471/14 ,  C07D207/42 ,  C07D403/04 ,  C07D231/16

CPC classification number: C07D471/14 ,  C07D207/42 ,  C07D231/16 ,  C07D403/04

Abstract: The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.

公开(公告)号：US20250026767A1

公开(公告)日：2025-01-23

申请号：US18908888

申请日：2024-10-08

Applicant: Bristol-Myers Squibb Company

Inventor： Roxana F. Schlam ,  Nicolas Cuniere ,  Victoria A. Mbachu ,  Zhongping Shi ,  Petinka I. Vlahova

IPC: C07D513/04 ,  A61K31/433 ,  A61K45/06 ,  A61P7/02 ,  C07C55/10 ,  C07C59/265

Abstract: The present invention relates to co-crystals of the compound of formula (I). wherein the co-former molecule is succinic acid or citric acid. processes for the preparation of the co-crystal. pharmaceutical compositions thereof, and methods of using the co-crystals for treating or preventing thromboembolic disorders.

公开(公告)号：US12129264B2

公开(公告)日：2024-10-29

申请号：US17415237

申请日：2019-12-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Roxana F. Schlam ,  Nicolas Cuniere ,  Victoria A. Mbachu ,  Zhongping Shi ,  Petinka I. Vlahova

IPC: C07D513/04 ,  A61K31/433 ,  A61K45/06 ,  A61P7/02 ,  C07C55/10 ,  C07C59/265

CPC classification number: C07D513/04 ,  A61K31/433 ,  A61K45/06 ,  A61P7/02 ,  C07C55/10 ,  C07C59/265 ,  C07B2200/13

Abstract: The present invention relates to co-crystals of the compound of formula (I), wherein the co-former molecule is succinic acid or citric acid, processes for the preparation of the co-crystal, pharmaceutical compositions thereof, and methods of using the co-crystals for treating or preventing thromboembolic disorders.

公开(公告)号：US20160229854A1

公开(公告)日：2016-08-11

申请号：US14914330

申请日：2014-08-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Martin D. Eastgate ,  Gregory L. Beutner ,  Benjamin Cohen ,  Nicolas Cuniere ,  Lopa V. Desai ,  Monica Fitzgerald ,  Qi Gao ,  Michael Bryan Hay ,  Michael Joseph Lawler ,  Paul C. Lobben ,  Christopher S. Regens ,  Thorsten Rosner ,  Neil Strotman ,  Carolyn S. Wei ,  Yi Xiao ,  Bin Zheng ,  Keming Zhu

IPC: C07D471/14 ,  C07D403/04 ,  C07D231/16 ,  C07D207/42

CPC classification number: C07D471/14 ,  C07D207/42 ,  C07D231/16 ,  C07D403/04

Abstract: The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.

Abstract translation: 本发明涉及一种合成N，N-二环丙基-4-（1,5-二甲基-1H-吡唑-3-基氨基）-6-乙基-1-甲基-1,6-二氢咪唑并[4,5 d]吡咯并[2,3-b]吡啶-7-甲酰胺，其化学式（I）化合物（I）目前正在临床试验中用于治疗骨髓增生性疾病，如多发性红血球病，血小板减少症和原发性骨髓纤维化。